249 related articles for article (PubMed ID: 34533900)
1. Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland.
Barner-Rasmussen N; Pukkala E; Hadkhale K; Färkkilä M
United European Gastroenterol J; 2021 Dec; 9(10):1128-1135. PubMed ID: 34533900
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland.
Barner-Rasmussen N; Pukkala E; Jussila A; Färkkilä M
Scand J Gastroenterol; 2020 Jan; 55(1):74-81. PubMed ID: 31902255
[No Abstract] [Full Text] [Related]
4. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience.
Goss JA; Shackleton CR; Farmer DG; Arnaout WS; Seu P; Markowitz JS; Martin P; Stribling RJ; Goldstein LI; Busuttil RW
Ann Surg; 1997 May; 225(5):472-81; discussion 481-3. PubMed ID: 9193175
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of cholangiocarcinoma.
Bergquist A; von Seth E
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):221-32. PubMed ID: 25966423
[TBL] [Abstract][Full Text] [Related]
6. Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease.
Manninen P; Karvonen AL; Laukkarinen J; Aitola P; Huhtala H; Collin P
Scand J Gastroenterol; 2015 Apr; 50(4):423-8. PubMed ID: 25636976
[TBL] [Abstract][Full Text] [Related]
7. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.
Javle M; Lee S; Azad NS; Borad MJ; Kate Kelley R; Sivaraman S; Teschemaker A; Chopra I; Janjan N; Parasuraman S; Bekaii-Saab TS
Oncologist; 2022 Oct; 27(10):874-883. PubMed ID: 35972334
[TBL] [Abstract][Full Text] [Related]
8. Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review.
Song J; Li Y; Bowlus CL; Yang G; Leung PSC; Gershwin ME
Clin Rev Allergy Immunol; 2020 Feb; 58(1):134-149. PubMed ID: 31463807
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.
Taghavi SA; Eshraghian A; Niknam R; Sivandzadeh GR; Bagheri Lankarani K
Expert Rev Gastroenterol Hepatol; 2018 Jun; 12(6):575-584. PubMed ID: 29781738
[TBL] [Abstract][Full Text] [Related]
10. Cholangiocarcinoma in patients with primary sclerosing cholangitis.
Fung BM; Tabibian JH
Curr Opin Gastroenterol; 2020 Mar; 36(2):77-84. PubMed ID: 31850928
[TBL] [Abstract][Full Text] [Related]
11. Primary sclerosing cholangitis-associated cholangiocarcinoma: special considerations and best practices.
Fung BM; Tabibian JH
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):487-496. PubMed ID: 33682586
[No Abstract] [Full Text] [Related]
12. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.
Izquierdo-Sanchez L; Lamarca A; La Casta A; Buettner S; Utpatel K; Klümpen HJ; Adeva J; Vogel A; Lleo A; Fabris L; Ponz-Sarvise M; Brustia R; Cardinale V; Braconi C; Vidili G; Jamieson NB; Macias RI; Jonas JP; Marzioni M; Hołówko W; Folseraas T; Kupčinskas J; Sparchez Z; Krawczyk M; Krupa Ł; Scripcariu V; Grazi GL; Landa-Magdalena A; Ijzermans JN; Evert K; Erdmann JI; López-López F; Saborowski A; Scheiter A; Santos-Laso A; Carpino G; Andersen JB; Marin JJ; Alvaro D; Bujanda L; Forner A; Valle JW; Koerkamp BG; Banales JM
J Hepatol; 2022 May; 76(5):1109-1121. PubMed ID: 35167909
[TBL] [Abstract][Full Text] [Related]
13. New epidemiologic trends in cholangiocarcinoma.
Pascale A; Rosmorduc O; Duclos-Vallée JC
Clin Res Hepatol Gastroenterol; 2023 Nov; 47(9):102223. PubMed ID: 37797807
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.
Burak K; Angulo P; Pasha TM; Egan K; Petz J; Lindor KD
Am J Gastroenterol; 2004 Mar; 99(3):523-6. PubMed ID: 15056096
[TBL] [Abstract][Full Text] [Related]
15. Clinical presentation, risk factors and staging systems of cholangiocarcinoma.
Plentz RR; Malek NP
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):245-52. PubMed ID: 25966425
[TBL] [Abstract][Full Text] [Related]
16. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.
Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
Am J Surg Pathol; 2010 Jan; 34(1):27-34. PubMed ID: 19898228
[TBL] [Abstract][Full Text] [Related]
17. Aspirin use and the risk of cholangiocarcinoma.
Choi J; Ghoz HM; Peeraphatdit T; Baichoo E; Addissie BD; Harmsen WS; Therneau TM; Olson JE; Chaiteerakij R; Roberts LR
Hepatology; 2016 Sep; 64(3):785-96. PubMed ID: 26940227
[TBL] [Abstract][Full Text] [Related]
18. Primary sclerosing cholangitis and cholangiocarcinoma.
Lazaridis KN; Gores GJ
Semin Liver Dis; 2006 Feb; 26(1):42-51. PubMed ID: 16496232
[TBL] [Abstract][Full Text] [Related]
19. De Novo Colorectal and Pancreatic Cancer in Liver-Transplant Recipients: Identifying the Higher-Risk Populations.
Nasser-Ghodsi N; Mara K; Watt KD
Hepatology; 2021 Aug; 74(2):1003-1013. PubMed ID: 33544906
[TBL] [Abstract][Full Text] [Related]
20. Comparison of concomitant and subsequent cholangiocarcinomas associated with hepatolithiasis: Clinical implications.
Lin CC; Lin PY; Chen YL
World J Gastroenterol; 2013 Jan; 19(3):375-80. PubMed ID: 23372360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
